FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211231714> ?p ?o ?g. }

• W3211231714 endingPage "1747" @default.
• W3211231714 startingPage "1747" @default.
• W3211231714 abstract "Protein aggregation constitutes a recurring complication in the manufacture and clinical use of therapeutic monoclonal antibodies (mAb) and mAb derivatives. Antibody aggregates can reduce production yield, cause immunogenic reactions, decrease the shelf-life of the pharmaceutical product and impair the capacity of the antibody monomer to bind to its cognate antigen. A common strategy to tackle protein aggregation involves the identification of surface-exposed aggregation-prone regions (APR) for replacement through protein engineering. It was shown that the insertion of N-glycosylation sequons on amino acids proximal to an aggregation-prone region can increase the physical stability of the protein by shielding the APR, thus preventing self-association of antibody monomers. We recently implemented this approach in the Fab region of full-size adalimumab and demonstrated that the thermodynamic stability of the Fab domain increases upon N-glycosite addition. Previous experimental data reported for this technique have lacked appropriate confirmation of glycan occupancy and structural characterization of the ensuing glycan profile. Herein, we mutated previously identified candidate positions on the Fab domain of Trastuzumab and employed tandem mass spectrometry to confirm attachment and obtain a detailed N-glycosylation profile of the mutants. The Trastuzumab glycomutants displayed a glycan profile with significantly higher structural heterogeneity compared to the HEK Trastuzumab antibody, which contains a single N-glycosylation site per heavy chain located in the CH2 domain of the Fc region. These findings suggest that Fab N-glycosites have higher accessibility to enzymes responsible for glycan maturation. Further, we have studied effects on additional glycosylation on protein stability via accelerated studies by following protein folding and aggregation propensities and observed that additional glycosylation indeed enhances physical stability and prevent protein aggregation. Our findings shed light into mAb glycobiology and potential implications in the application of this technique for the development of biobetter antibodies." @default.
• W3211231714 created "2021-11-08" @default.
• W3211231714 creator A5014289911 @default.
• W3211231714 creator A5037318878 @default.
• W3211231714 creator A5050749540 @default.
• W3211231714 creator A5064279301 @default.
• W3211231714 creator A5073917709 @default.
• W3211231714 creator A5074219458 @default.
• W3211231714 creator A5074253353 @default.
• W3211231714 date "2021-10-20" @default.
• W3211231714 modified "2023-09-23" @default.
• W3211231714 title "Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity" @default.
• W3211231714 cites W1976736354 @default.
• W3211231714 cites W1978617599 @default.
• W3211231714 cites W1984854392 @default.
• W3211231714 cites W1992836113 @default.
• W3211231714 cites W1993838215 @default.
• W3211231714 cites W2028489320 @default.
• W3211231714 cites W2046231291 @default.
• W3211231714 cites W2055674384 @default.
• W3211231714 cites W2065419141 @default.
• W3211231714 cites W2067608620 @default.
• W3211231714 cites W2069948193 @default.
• W3211231714 cites W2074726906 @default.
• W3211231714 cites W2086820922 @default.
• W3211231714 cites W2088953080 @default.
• W3211231714 cites W2093033417 @default.
• W3211231714 cites W2118293752 @default.
• W3211231714 cites W2119812267 @default.
• W3211231714 cites W2126075421 @default.
• W3211231714 cites W2146612842 @default.
• W3211231714 cites W2160241845 @default.
• W3211231714 cites W2166420822 @default.
• W3211231714 cites W2203688599 @default.
• W3211231714 cites W2411303265 @default.
• W3211231714 cites W2475096707 @default.
• W3211231714 cites W2558801358 @default.
• W3211231714 cites W2558911501 @default.
• W3211231714 cites W2570336065 @default.
• W3211231714 cites W2575991276 @default.
• W3211231714 cites W2592091368 @default.
• W3211231714 cites W2596798204 @default.
• W3211231714 cites W2767164921 @default.
• W3211231714 cites W2789361433 @default.
• W3211231714 cites W2790763558 @default.
• W3211231714 cites W2793622708 @default.
• W3211231714 cites W2809002406 @default.
• W3211231714 cites W2811019845 @default.
• W3211231714 cites W2889506936 @default.
• W3211231714 cites W2897920080 @default.
• W3211231714 cites W2915483287 @default.
• W3211231714 cites W2942911318 @default.
• W3211231714 cites W2948534853 @default.
• W3211231714 cites W3011937534 @default.
• W3211231714 cites W3021526622 @default.
• W3211231714 cites W317387912 @default.
• W3211231714 doi "https://doi.org/10.3390/pharmaceutics13111747" @default.
• W3211231714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8620955" @default.
• W3211231714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34834161" @default.
• W3211231714 hasPublicationYear "2021" @default.
• W3211231714 type Work @default.
• W3211231714 sameAs 3211231714 @default.
• W3211231714 citedByCount "1" @default.
• W3211231714 countsByYear W32112317142022 @default.
• W3211231714 crossrefType "journal-article" @default.
• W3211231714 hasAuthorship W3211231714A5014289911 @default.
• W3211231714 hasAuthorship W3211231714A5037318878 @default.
• W3211231714 hasAuthorship W3211231714A5050749540 @default.
• W3211231714 hasAuthorship W3211231714A5064279301 @default.
• W3211231714 hasAuthorship W3211231714A5073917709 @default.
• W3211231714 hasAuthorship W3211231714A5074219458 @default.
• W3211231714 hasAuthorship W3211231714A5074253353 @default.
• W3211231714 hasBestOaLocation W32112317141 @default.
• W3211231714 hasConcept C108625454 @default.
• W3211231714 hasConcept C121608353 @default.
• W3211231714 hasConcept C125823703 @default.
• W3211231714 hasConcept C159654299 @default.
• W3211231714 hasConcept C170493617 @default.
• W3211231714 hasConcept C185592680 @default.
• W3211231714 hasConcept C203014093 @default.
• W3211231714 hasConcept C206212055 @default.
• W3211231714 hasConcept C2777313579 @default.
• W3211231714 hasConcept C2779786085 @default.
• W3211231714 hasConcept C30324644 @default.
• W3211231714 hasConcept C530470458 @default.
• W3211231714 hasConcept C542903549 @default.
• W3211231714 hasConcept C54355233 @default.
• W3211231714 hasConcept C55493867 @default.
• W3211231714 hasConcept C86803240 @default.
• W3211231714 hasConceptScore W3211231714C108625454 @default.
• W3211231714 hasConceptScore W3211231714C121608353 @default.
• W3211231714 hasConceptScore W3211231714C125823703 @default.
• W3211231714 hasConceptScore W3211231714C159654299 @default.
• W3211231714 hasConceptScore W3211231714C170493617 @default.
• W3211231714 hasConceptScore W3211231714C185592680 @default.
• W3211231714 hasConceptScore W3211231714C203014093 @default.
• W3211231714 hasConceptScore W3211231714C206212055 @default.
• W3211231714 hasConceptScore W3211231714C2777313579 @default.

• next